Transthyretin Amyloid Polyneuropathy
📧 Sign up to get email alerts when something new happens for Transthyretin Amyloid Polyneuropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy [Phase 4]
Phase 4 clinical trial evaluating the efficacy and safety of Tafamidis meglumine soft capsules in adult patients with transthyretin amyloid …
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients [Phase 4]
Phase 4 clinical trial update on tafamidis meglumine for transthyretin amyloid polyneuropathy has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients [Phase 4]
A Phase 4 clinical trial update evaluating tafamidis for transthyretin amyloidosis, focusing on stabilization, safety, tolerability, and eff…
-
FDA approval · 2021-06-01FDA Approved: VYNDAMAX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for VYNDAMAX (tafamidis) submitted by Pfizer Laboratories Div Pfizer Inc.